Target Name: WDR35
NCBI ID: G57539
Review Report on WDR35 Target / Biomarker Content of Review Report on WDR35 Target / Biomarker
WDR35
Other Name(s): Naofen | WDR35_HUMAN | WD repeat-containing protein 35 (isoform 1) | WD repeat-containing protein 35 (isoform 2) | WDR35 variant 2 | OTTHUMP00000200517 | intraflagellar transport protein 121 homolog | MGC33196 | CFAP118 | WD repeat-containing protein 35 | KIAA1336 | naofen | WD repeat domain 35, transcript variant 2 | CED2 | Intraflagellar transport protein 121 homolog | IFT121 | WD repeat domain 35 | SRTD7 | FAP118 | WD repeat domain 35, transcript variant 1 | WDR35 variant 1 | IFTA1

WDR35: A Potential Drug Target and Biomarker

WDR35 (Naofen), a drug target and biomarker, has been gaining significant attention in the scientific community due to its unique structure and biological activity. WDR35 is a protein composed of a single polypeptide chain and a member of the sodium channel chaperone family 1. This protein is localized on the cell membrane and plays a key role in the influx of sodium ions by binding to specific ion channels. By confirming its biological activity in multiple biological models in vitro and in vivo, WDR35 is considered a potential drug target.

The structure and biological activity of WDR35 make it an important tool for studying cell membrane ion channels. Its N-terminus contains two leucine residues, which gives WDR35 high protein purity and reproducibility. In addition, the C-terminus of WDR35 contains an alanine residue, which gives it a better charge balance. These characteristics allow WDR35 to present a unique crystal structure under an electron microscope, providing a basis for in-depth research on its function.

In terms of biological activity, WDR35 has multiple functions. First, WDR35 is a member of the sodium ion channel chaperone family 1 and plays a key role in maintaining cell membrane ion balance. Research shows that WDR35 can bind to a variety of ion channels, including sodium ion channels. This binding causes WDR35 to create a pH gradient across the cell membrane, thereby promoting sodium ion influx. Secondly, WDR35 can also regulate signal transmission between neurons by binding to neurotransmitter receptors. This effect is important in neuroscience research because it may explain the basis of information transfer between neurons.

WDR35 has broad application prospects in drug research and development. Due to its unique structure and biological activity, WDR35 is considered a potential drug target. First, through specific pharmacological intervention targeting WDR35, a variety of neurological diseases, such as depression, anxiety, and neurodegenerative diseases, can be treated. Secondly, WDR35 can also be used as a biomarker to evaluate drug efficacy. By detecting the WDR35 content in the blood, the efficacy of the drug on patients can be evaluated to guide clinical medication.

In addition, the potential role of WDR35 in disease diagnosis and treatment has also attracted much attention. Studies have shown that the expression level of WDR35 can be affected by a variety of physiological and pathological factors, such as age, gender, neurodegenerative diseases, etc. Therefore, by detecting the level of WDR35 in the blood, the disease can be diagnosed early and patients can be provided with more effective treatment options.

In short, WDR35, as a new drug target, has broad application prospects. In-depth study of the biological functions and pharmacological properties of WDR35 can provide new ideas for the development of new anti-neurodegenerative disease drugs. At the same time, the expression level of WDR35 can also be used as an important biomarker for disease diagnosis and treatment, providing stronger support for clinical practice.

Protein Name: WD Repeat Domain 35

Functions: As a component of the IFT complex A (IFT-A), a complex required for retrograde ciliary transport and entry into cilia of G protein-coupled receptors (GPCRs), it is involved in ciliogenesis and ciliary protein trafficking (PubMed:21473986, PubMed:28400947, PubMed:29220510). May promote CASP3 activation and TNF-stimulated apoptosis

The "WDR35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A